Endometrial cancer (EC) is one of the most common gynecologic cancers. In recent years, research has focused on the genetic characteristics of the tumors to detail their prognosis and tailor therapy. In the case of EC, genetic mutations have been shown to underlie their formation. It is very important to know the mechanisms of EC formation related to mutations induced by estrogen, among other things. Noncoding RNAs (ncRNAs), composed of nucleotide transcripts with very low protein-coding capacity, are proving to be important. Their expression patterns in many malignancies can inhibit tumor formation and progression. They also regulate protein coding at the epigenetic, transcriptional, and posttranscriptional levels. MicroRNAs (miRNAs), several varieties of which are associated with normal endometrium as well as its tumor, also play a particularly important role in gene expression. MiRNAs and long noncoding RNAs (lncRNAs) affect many pathways in EC tissues and play important roles in cancer development, invasion, and metastasis, as well as resistance to anticancer drugs through mechanisms such as suppression of apoptosis and progression of cancer stem cells. It is also worth noting that miRNAs are highly precise, sensitive, and robust, making them potential markers for diagnosing gynecologic cancers and their progression. Unfortunately, as the incidence of EC increases, treatment becomes challenging and is limited to invasive tools. The prospect of using microRNAs as potential candidates for diagnostic and therapeutic use in EC seems promising. Exosomes are extracellular vesicles that are released from many types of cells, including cancer cells. They contain proteins, DNA, and various types of RNA, such as miRNAs. The noncoding RNA components of exosomes vary widely, depending on the physiology of the tumor tissue and the cells from which they originate. Exosomes contain both DNA and RNA and have communication functions between cells. Exosomal miRNAs mediate communication between EC cells, tumor-associated fibroblasts (CAFs), and tumor-associated macrophages (TAMs) and play a key role in tumor cell proliferation and tumor microenvironment formation. Oncogenes carried by tumor exosomes induce malignant transformation of target cells. During the synthesis of exosomes, various factors, such as genetic and proteomic data are upregulated. Thus, they are considered an interesting therapeutic target for the diagnosis and prognosis of endometrial cancer by analyzing biomarkers contained in exosomes. Expression of miRNAs, particularly miR-15a-5p, was elevated in exosomes derived from the plasma of EC patients. This may suggest the important utility of this biomarker in the diagnosis of EC. In recent years, researchers have become interested in the topic of prognostic markers for EC, as there are still too few identified markers to support the limited treatment of endometrial cancer. Further research into the effects of ncRNAs and exosomes on EC may allow for cancer treatment breakthroughs.

Clinical Research Development Unit Imam Khomeini Hospital Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran

Department of Obstetrics and Gynecology School of Medicine Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran

Department of Obstetrics and Gynecology School of Medicine Hamadan University of Medical Sciences Hamadan Iran

Department of Obstetrics and Gynecology University Hospital and Masaryk University Brno Czechia

Department of Veterinary Surgery Institute of Veterinary Medicine Nicolaus Copernicus University in Torun Torun Poland

Division of Anatomy Department of Human Morphology and Embryology Faculty of Medicine Wroclaw Medical University Wroclaw Poland

Division of Histology and Embryology Department of Human Morphology and Embryology Faculty of Medicine Wroclaw Medical University Wroclaw Poland

Fertility Infertility and Perinatology Research Center Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran

Hematology and Oncology Research Center Tabriz University of Medical Sciences Tabriz Iran

Physiology Graduate Program North Carolina State University Raleigh NC United States

Zobrazit více v PubMed

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. doi: 10.3322/caac.21660 PubMed DOI

Piergentili R, Zaami S, Cavaliere AF, Signore F, Scambia G, Mattei A, et al. . Non-coding RNAs as prognostic markers for endometrial cancer. Int J Mol Sci. (2021) 22:3151. doi: 10.3390/ijms22063151 PubMed DOI PMC

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistic. CA Cancer J Clin. (2023) 73:17–48. doi: 10.3322/caac.21763 PubMed DOI

Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecologic Oncol. (1983) 15:10–7. doi: 10.1016/0090-8258(83)90111-7 PubMed DOI

Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. . ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncology: Off J Eur Soc Med Oncol. (2016) 27:16–41. doi: 10.1093/annonc/mdv484 PubMed DOI

Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, et al. . FIGO staging of endometrial cancer: 2023. Int J Gynaecology Obstetrics: Off Organ Int Fed Gynaecology Obstetrics. (2023) 162:383–945. doi: 10.1002/ijgo.14923 PubMed DOI

Coll-de la Rubia E, Martinez-Garcia E, Dittmar G, Gil-Moreno A, Cabrera S, Colas E. Prognostic biomarkers in endometrial cancer: A systematic review and meta-analysis. J Clin Med. (2020) 9:1900. doi: 10.3390/jcm9061900 PubMed DOI PMC

Yao Y, Wang X, Guan J, Xie C, Zhang H, Yang J, et al. . Metabolomic differentiation of benign vs Malignant pulmonary nodules with high specificity via high-resolution mass spectrometry analysis of patient sera. Nat Commun. (2023) 14:2339. doi: 10.1038/s41467-023-37875-1 PubMed DOI PMC

Buergel T, Steinfeldt J, Ruyoga G, Pietzner M, Bizzarri D, Vojinovic D, et al. . Metabolomic profiles predict individual multidisease outcomes. Nat Med. (2022) 28:2309–20. doi: 10.1038/s41591-022-01980-3 PubMed DOI PMC

Liu S, Li W, Liang L, Zhou Y, Li Y. The regulatory relationship between transcription factor STAT3 and noncoding RNA. Cell Mol Biol Lett. (2024) 29:4. doi: 10.1186/s11658-023-00521-1 PubMed DOI PMC

Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. . Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. (2018) 560:382–86. doi: 10.1038/s41586-018-0392-8 PubMed DOI PMC

Eritja N, Navaridas R, Ruiz-Mitjana A, Vidal-Sabanés M, Egea J, Encinas M, et al. . Endometrial PTEN deficiency leads to SMAD2/3 nuclear translocation. Cancers (Basel). (2021) 13:4990. doi: 10.3390/cancers13194990 PubMed DOI PMC

Frąszczak K, Barczyński B. Characteristics of cancer stem cells and their potential role in endometrial cancer. Cancers (Basel). (2024) 16:1083. doi: 10.3390/cancers16061083 PubMed DOI PMC

Vallone C, Rigon G, Gulia C, Baffa A, Votino R, Morosetti G, et al. . Non-coding RNAs and endometrial cancer. Genes. (2018) 9:187. doi: 10.3390/genes9040187 PubMed DOI PMC

Ling H, Vincent K, Pichler M, Fodde R, Berindan-Neagoe I, Slack FJ, et al. . Junk DNA and the long non-coding RNA twist in cancer genetics. Oncogene. (2015) 34:5003–11. doi: 10.1038/onc.2014.456 PubMed DOI PMC

Muhammad N, Bhattacharya S, Steele R, Ray RB. Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3. Oncotarget. (2016) 7 (36):58595–605 doi: 10.18632/oncotarget.11193 PubMed DOI PMC

Shekibi M, Heng S, Nie G. MicroRNAs in the regulation of endometrial receptivity for embryo implantation. Int J Mol Sci. (2022) 23:6210. doi: 10.3390/ijms23116210 PubMed DOI PMC

Wang X, Wendel JRH, Emerson RE, Broaddus RR, Creighton CJ, Rusch DB, et al. . “Pten and dicer1 loss in the mouse uterus causes poorly differentiated endometrial adenocarcinoma. Oncogene. (2020) 39:6286–995. doi: 10.1038/s41388-020-01434-5 PubMed DOI PMC

Zhang C, Ji Q, Yang Y, Li Qi, Wang Z. Exosome: function and role in cancer metastasis and drug resistance. Technol Cancer Res Treat. (2018) 17:1533033818763450. doi: 10.1177/1533033818763450 PubMed DOI PMC

Park Y, Lee K, Kim SW, Lee MW, Kim B, Lee SG. Effects of induced exosomes from endometrial cancer cells on tumor activity in the presence of aurea helianthus extract. Molecules (Basel Switzerland). (2021) 26:2207. doi: 10.3390/molecules26082207 PubMed DOI PMC

Krylova SV, Feng D. The machinery of exosomes: biogenesis, release, and uptake. Int J Mol Sci. (2023) 24:1337. doi: 10.3390/ijms24021337 PubMed DOI PMC

Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet (London England). (2022) 399:1412–285. doi: 10.1016/S0140-6736(22)00323-3 PubMed DOI

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. . Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; (2024).

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. (2019) 144:1941–53. doi: 10.1002/ijc.31937 PubMed DOI

Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, et al. . Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncology: Off J Eur Soc Med Oncol. (2022) 33:860–775. doi: 10.1016/j.annonc.2022.05.009 PubMed DOI

Wojciechowska U, Barańska K, Miklewska M, Didkowska JA. Cancer incidence and mortality in Poland in 2020. Nowotwory J Oncol. (2023) 73:129–45. doi: 10.5603/NJO.2023.0026 DOI

Arthur RS, Kabat GC, Kim MY, Wild RA, Shadyab AH, Wactawski-Wende J, et al. . Metabolic syndrome and risk of endometrial cancer in postmenopausal women: A prospective study. Cancer Causes Control: CCC. (2019) 30:355–63. doi: 10.1007/s10552-019-01139-5 PubMed DOI PMC

Soslow RA, Tornos C, Park KJ, Malpica A, Matias-Guiu X, Oliva E, et al. . Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the international society of gynecological pathologists. Int J Gynecological Pathology: Off J Int Soc Gynecological Pathologists. (2019) 38 Suppl 1:S64–74. doi: 10.1097/PGP.0000000000000518 PubMed DOI PMC

Domchek SM, Robson ME. “Update on genetic testing in gynecologic cancer. J Clin Oncol. (2019) 37:2501–95. doi: 10.1200/JCO.19.00363 PubMed DOI PMC

Mukherjee P, Roy S, Ghosh D, Nandi SK. Role of animal models in biomedical research: a review. Lab Anim Res. (2022) 38. doi: 10.1186/s42826-022-00128-1 PubMed DOI PMC

Cho SY. Patient-derived xenografts as compatible models for precision oncology. Lab Anim Res. (2020) 36:14. doi: 10.1186/s42826-020-00045-1 PubMed DOI PMC

Imai T, Yoshida H, Machida Y, Kuramochi M, Ichikawa H, Kubo T, et al. . Alteration in molecular properties during establishment and passaging of endometrial carcinoma patient-derived xenografts. Sci Rep. (2023) 13(1):8511. doi: 10.1038/s41598-023-35703-6 PubMed DOI PMC

Kato S, Fushimi K, Yabuki Y, Maru Y, Hasegawa S, Matsuura T, et al. . Precision modeling of gall bladder cancer patients in mice based on orthotopic implantation of organoid-derived tumor buds. Oncogenesis. (2021) 10:1–13. doi: 10.1038/s41389-021-00322-1 PubMed DOI PMC

Maru Y, Hippo Y. Two-way development of the genetic model for endometrial tumorigenesis in mice: current and future perspectives. Front Genet. (2021) 12:798628. doi: 10.3389/fgene.2021.798628 PubMed DOI PMC

Wang J, Jia N, Lyv T, Wang C, Tao X, Wong KK, et al. . Paired box 2 promotes progression of endometrial cancer via regulating cell cycle pathway. J Cancer. (2018) 9:3743–54. doi: 10.7150/jca.22418 PubMed DOI PMC

Wang L, Zuo X, Xie K, Wei D. The role of CD44 and cancer stem cells. Methods Mol Biol. (2018) 1692:31–42. doi: 10.1007/978-1-4939-7401-6_3 PubMed DOI

Khizer K, Padda J, Khedr A, Tasnim F, Al-Ewaidat OA, Patel V, et al. . Paired-box gene 8 (PAX8) and its association with epithelial carcinomas. Cureus. (2021) 13(8):e17208. doi: 10.7759/cureus.17208 PubMed DOI PMC

Monsivais D, Peng J, Kang Y, Matzuk MM. Activin-like kinase 5 (ALK5) inactivation in the mouse uterus results in metastatic endometrial carcinoma. Proc Natl Acad Sci United States America. (2019) 116:3883–92. doi: 10.1073/pnas.1806838116 PubMed DOI PMC

Ruiz-Mitjana A, Vidal-Sabanés M, Navaridas Raúl, Perramon-Güell A, Yeramian A, Nicholson-Sabaté N, et al. . Metformin exhibits antineoplastic effects on pten-deficient endometrial cancer by interfering with TGF-β and P38/ERK MAPK signalling. Biomedicine Pharmacotherapy = Biomedecine Pharmacotherapie. (2023) 168:115817. doi: 10.1016/j.biopha.2023.115817 PubMed DOI

Fang X, Ni N, Wang X, Tian Y, Ivanov I, Rijnkels M, et al. . “EZH2 and endometrial cancer development: insights from a mouse model. Cells. (2022) 11:9095. doi: 10.3390/cells11050909 PubMed DOI PMC

Franklin MR, Platero S, Saini KS, Curigliano G, Anderson S. Immuno-oncology trends: Preclinical models, biomarkers, and clinical development. J ImmunoTherapy Cancer. (2022) 10(1):e003231. doi: 10.1136/jitc-2021-003231 PubMed DOI PMC

Nyen T, Moiola CP, Colas E, Annibali D, Amant F. Modeling endometrial cancer: Past, present, and future. Int J Mol Sci. (2018) 19(8):2348. doi: 10.3390/ijms19082348 PubMed DOI PMC

Espedal H, Berg HF, Fonnes T, Fasmer KE, Krakstad C, Haldorsen IS. Feasibility and utility of MRI and dynamic 18F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer. J Trans Med. (2021) 19(1):406. doi: 10.1186/s12967-021-03086-9 PubMed DOI PMC

Espedal H, Fonnes T, Fasmer KE, Krakstad C, Haldorsen IS. Imaging of preclinical endometrial cancer models for monitoring tumor progression and response to targeted therapy. Cancers. (2019) 11(12):1885. doi: 10.3390/cancers11121885 PubMed DOI PMC

Chen J, Dai S, Zhao L, Peng Y, Sun C, Peng H, et al. . A new type of endometrial cancer models in mice revealing the functional roles of genetic drivers and exploring their susceptibilities. Advanced Science. (2023) 10(24):e2300383. doi: 10.1002/advs.202300383 PubMed DOI PMC

Yu K, Huang Z-Y, Xu X-L, Li J, Fu X-W, Deng S-L. Estrogen receptor function: impact on the human endometrium. Front Endocrinol. (2022) 13:827724. doi: 10.3389/fendo.2022.827724 PubMed DOI PMC

Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ. Estrog en signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol. (2008) 70:165–90. doi: 10.1146/annurev.physiol.70.113006.100518 PubMed DOI

Wang C, Prossnitz ER, Roy SK. Expression of G protein-coupled receptor 30 in the hamster ovary: differential regulation by gonadotropins and steroid hormones. Endocrinology. (2007) 148:4853–64. doi: 10.1210/en.2007-0727 PubMed DOI

Otto C, Fuchs I, Kauselmann G, Kern H, Zevnik B, Andreasen P, et al. . GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol Reprod. (2009) 80:34–41. doi: 10.1095/biolreprod.108.071175 PubMed DOI

Mamat Yusof MN, Chew KT, Kampan NC, Shafiee MN. Expression of PD-1 and PD-L1 in endometrial cancer: molecular and clinical significance. Int J Mol Sci. (2023) 24:15233. doi: 10.3390/ijms242015233 PubMed DOI PMC

Wang J, Song T, Zhou S, Kong X. YAP promotes the Malignancy of endometrial cancer cells via regulation of IL-6 and IL-11. Mol Med. (2019) 25:32. doi: 10.1186/s10020-019-0103-4 PubMed DOI PMC

Khan TH, Srivastava N, Srivastava A, Sareen A, Mathur RK, Chande AG, et al. . SHP-1 plays a crucial role in CD40 signaling reciprocity. J Immunol. (2014) 193:3644–53. doi: 10.4049/jimmunol.1400620 PubMed DOI

Murugaiyan G, Martin S, Saha B. CD40-induced countercurrent conduits for tumor escape or elimination? Trends Immunol. (2007) 28:467–73. doi: 10.1016/j.it.2007.08.010 PubMed DOI

Dumas G, Dufresne M, Asselin É, Girouard J, Carrier C, Reyes-Moreno C. CD40 pathway activation reveals dual function for macrophages in human endometrial cancer cell survival and invasion. Cancer Immunol Immunother. (2013) 62:273–83. doi: 10.1007/s00262-012-1333-2 PubMed DOI PMC

Zhou Y, Richmond A, Yan C. Harnessing the potential of CD40 agonism in cancer therapy. Cytokine Growth Factor Rev. (2024) 75:40–56. doi: 10.1016/j.cytogfr.2023.11.002 PubMed DOI PMC

Zhang X, Kiapour N, Kapoor S, Khan T, Thamilarasan M, Tao Y, et al. . IL-11 induces encephalitogenic th17 cells in multiple sclerosis and experimental autoimmune encephalomyelitis. J Immunol. (2019) 203:1142–50. doi: 10.4049/jimmunol.1900311 PubMed DOI PMC

Seyedsadr M, Wang Y, Elzoheiry M, Shree Gopal S, Jang S, Duran G, et al. . IL-11 induces NLRP3 inflammasome activation in monocytes and inflammatory cell migration to the central nervous system. Proc Natl Acad Sci U S A. (2023) 120:e2221007120. doi: 10.1073/pnas.2221007120 PubMed DOI PMC

Ray I, Meira LB, Michael A, Ellis PE. Adipocytokines and disease progression in endometrial cancer: a systematic review. Cancer Metastasis Rev. (2022) 41:211–42. doi: 10.1007/s10555-021-10002-6 PubMed DOI PMC

Tarique M, Naz H, Suhail M, Turan A, Saini C, Muhammad N, et al. . Differential expression of programmed death 1 (PD-1) on various immune cells and its role in human leprosy. Front Immunol. (2023) 14:1138145. doi: 10.3389/fimmu.2023.1138145 PubMed DOI PMC

Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy? Oncoimmunology. (2017) 7:e1364828. doi: 10.1080/2162402X.2017.1364828 PubMed DOI PMC

Shen X, Zhang L, Li J, Li Y, Wang Y, Xu ZX. Recent findings in the regulation of programmed death ligand 1 expression. Front Immunol. (2019) 10:1337. doi: 10.3389/fimmu.2019.01337 PubMed DOI PMC

Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. (2020) 10:727–42. PubMed PMC

Bellucci R, Martin A, Bommarito D, Wang K, Hansen SH, Freeman GJ, et al. . Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology. (2015) 4:e1008824. doi: 10.1080/2162402X.2015.1008824 PubMed DOI PMC

Nunes-Xavier CE, Angulo JC, Pulido R, López JI. A critical insight into the clinical translation of PD-1/PD-L1 blockade therapy in clear cell renal cell carcinoma. Curr Urol Rep. (2019) 20:1. doi: 10.1007/s11934-019-0866-8 PubMed DOI

Ren D, Hua Y, Yu B, Ye X, He Z, Li C, et al. . Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol Cancer. (2020) 19:19. doi: 10.1186/s12943-020-1144-6 PubMed DOI PMC

June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. (2018) 359:1361–5. doi: 10.1126/science.aar6711 PubMed DOI

Sadelain M, Brentjens R, Riviere I. 2013. The basic principles of chimeric antigen receptor (CAR) design.”. Cancer Disc. (2013) 3 (4):388–98 doi: 10.1158/2159-8290.CD-12-0548 PubMed DOI PMC

Khan TH, Muhammad N, Tarique M, Usmani D, Sarode A.Y, Naz H. The role of cancer-specific target antigens in CAR T cell therapy in hematological Malignancies. Curr Tissue Microenviron Rep. (2024) 5(2):1–7. doi: 10.1007/s43152-024-00055-4 DOI

Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. (2020) 17:147–67. doi: 10.1038/s41571-019-0297-y PubMed DOI PMC

Yeware A, Helton A, Dong Y, Dong C, Pritchard J, Mineishi S, et al. . Novel fourth generation-like CARmiR cells release therapeutic miRNA via exosomes and enhance glioblastoma cell killing activity. Biochem Eng J. (2023) 199:109068. doi: 10.1016/j.bej.2023.109068 DOI

Wang L, Bu P, Ai Y, Srinivasan T, Chen HJ, Xiang K, et al. . A long non-coding RNA targets microRNA miR-34a to regulate colon cancer stem cell asymmetric division. Elife. (2016) 5:e14620. doi: 10.7554/eLife.14620 PubMed DOI PMC

Li WJ, Wang Y, Liu R, Kasinski AL, Shen H, Slack FJ, et al. . MicroRNA-34a: potent tumor suppressor, cancer stem cell inhibitor, and potential anticancer therapeutic. Front Cell Dev Biol. (2021) 9:640587. doi: 10.3389/fcell.2021.640587 PubMed DOI PMC

Papaccio F, Paino F, Regad T, Papaccio G, Desiderio V, Tirino V. Concise review: cancer cells, cancer stem cells, and mesenchymal stem cells: influence in cancer development. Stem Cells Transl Med. (2017) 6:2115–25. doi: 10.1002/sctm.17-0138 PubMed DOI PMC

Adcock IM, Caramori G, Barnes PJ. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration. (2011) 81:265–84. doi: 10.1159/000324601 PubMed DOI

Yan X, Luo H, Zhou X, Zhu B, Wang Y, Bian X. "Identification of CD90 as a marker for lung cancer stem cells in A549 and H446 cell lines". Oncol Rep. (2013) 30(6):2733–40. doi: 10.3892/or.2013.2784 PubMed DOI

Cao M, Liu Z, You D, Pan Y, Zhang Q. TMT-based quantitative proteomic analysis of spheroid cells of endometrial cancer possessing cancer stem cell properties. Stem Cell Res Ther. (2023) 14:119. doi: 10.1186/s13287-023-03348-x PubMed DOI PMC

Das S, Khan TH, Sarkar D. Comprehensive review on the effect of stem cells in cancer progression. Curr Tissue Microenviron Rep. (2024) 5:39–59. doi: 10.1007/s43152-024-00053-6 DOI

Hu Y, Dong Z, Liu K. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. J Exp Clin Cancer research : CR. (2024) 43:23. doi: 10.1186/s13046-024-02949-5 PubMed DOI PMC

Sun J, Du Y, Song Q, Nan J, Guan P, Guo J, et al. . E2F is required for STAT3-mediated upregulation of cyclin B1 and cdc2 expressions and contributes to G2-M phase transition. Acta Biochim Et Biophys Sin. (2019) 51:313–22. doi: 10.1093/abbs/gmy174 PubMed DOI

Shen L, Zhang C, Cui K, Liang X, Zhu G. Low-density lipoprotein contributes to endometrial carcinoma cell proliferation, migration, and invasion by activating the JAK-STAT signaling pathway. Analytical Cell Pathol (Amsterdam). (2023) 2023:4015167. doi: 10.1155/2023/4015167 PubMed DOI PMC

Wang J, He X, Jia Z, Yan A, Xiao K, Liu S, et al. . Shenqi fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway. Pharm Biol. (2024) 62:33–41. doi: 10.1080/13880209.2023.2292266 PubMed DOI PMC

Wang L, Lyu C, Stadlbauer B, Buchner A, Nößner E, Pohla H. Berbamine targets cancer stem cells and reverses cabazitaxel resistance via inhibiting IGF2BP1 and P-STAT3 in prostate cancer. Prostate. (2024) 84:131–47. doi: 10.1002/pros.24632 PubMed DOI

Luo Xu, Ye Z, Xu C, Chen H, Dai S, Chen W, et al. . Corosolic acid enhances oxidative stress-induced apoptosis and senescence in pancreatic cancer cells by inhibiting the JAK2/STAT3 pathway. Mol Biol Rep. (2024) 51:176. doi: 10.1007/s11033-023-09105-w PubMed DOI

Solaimuthu B, Khatib A, Tanna M, Karmi A, Hayashi A, Rmaileh AA, et al. . The exostosin glycosyltransferase 1/STAT3 axis is a driver of breast cancer aggressiveness. Proc Natl Acad Sci United States America. (2024) 121:e2316733121. doi: 10.1073/pnas.2316733121 PubMed DOI PMC

Garg M, Shanmugam MK, Bhardwaj V, Goel A, Gupta R, Sharma A, et al. . “The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy. Medicinal Res Reviews grudzień. (2020). doi: 10.1002/med.21761 PubMed DOI

Che Q, Xiao X, Liu M, Lu Y, Dong X, Liu S. IL-6 promotes endometrial cancer cells invasion and migration through signal transducers and activators of transcription 3 signaling pathway. Pathol Res Pract. (2019) 215:152392. doi: 10.1016/j.prp.2019.03.020 PubMed DOI

Richenberg G, Francis A, Owen CN, Gray V, Robinson T, Gabriel AA, et al. . The tumor multi-omic landscape of endometrial cancers developed on a germline genetic background of adiposity. medRxiv [Preprint]. (2023) 10:2023.10.09.23296765. doi: 10.1101/2023.10.09.23296765 DOI

Mahon KL, Sutherland SI, Lin HM, Stockler MR, Gurney H, Mallesara G, et al. . Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer. Prostate. (2024) 84:747–55. doi: 10.1002/pros.24691 PubMed DOI

Krishnamoorthy K, Natarajan SR, Veeraraghavan VP, Jayaraman S. Blueberry extract and its bioactive compounds mitigate oxidative stress and suppress human lung cancer cell (A549) growth by modulating the expression of P53/EGFR/STAT3/IL6-mediated signaling molecules. Cell Biochem Funct. (2024) 42:e4027. doi: 10.1002/cbf.4027 PubMed DOI

Xue Z, Li X, Zhang Y, Cao C, Zhou Q. IL6 induces mtDNA leakage to affect the immune escape of endometrial carcinoma via cGAS-STING. J Immunol Res. (2022) 2022:3815853. doi: 10.1155/2022/3815853 PubMed DOI PMC

Olivera M, Živković E, Subotički T, Diklić M, Đikić D, Vukotić M, et al. . Inflammation mediated angiogenesis in chronic lymphocytic leukemia. Ann Hematol. (2024) 103:2865–75. doi: 10.1007/s00277-024-05781-1 PubMed DOI

Tolomeo M, Cascio A. The multifaced role of STAT3 in cancer and its implication for anticancer therapy. Int J Mol Sci. (2021) 22:603. doi: 10.3390/ijms22020603 PubMed DOI PMC

Wu M, Song D, Li H, Yang Y, Ma X, Deng Sa, et al. . Negative regulators of STAT3 signaling pathway in cancers. Cancer Manage Res. (2019) 11:4957–69. doi: 10.2147/CMAR.S206175 PubMed DOI PMC

Li W, Lee M-R, Kim T, Kim YW, Cho M-Y. Activated STAT3 may participate in tumor progression through increasing CD133/survivin expression in early stage of colon cancer. Biochem Biophys Res Commun. (2018) 497:354–61. doi: 10.1016/j.bbrc.2018.02.084 PubMed DOI

Luna GCH, Imasa MS, Juat N, Hernandez KV, Sayo TM, Cristal-Luna G, et al. . Expression landscapes in non-small cell lung cancer shaped by the thyroid transcription factor 1. Lung Cancer (Amsterdam Netherlands). (2023) 176:121–31. doi: 10.1016/j.lungcan.2022.12.015 PubMed DOI

Chu Y, Wang Y, Peng W, Xu L, Liu M, Li J, et al. . STAT3 activation by IL-6 from adipose-derived stem cells promotes endometrial carcinoma proliferation and metastasis. Biochem Biophys Res Commun. (2018) 500:626–31. doi: 10.1016/j.bbrc.2018.04.121 PubMed DOI

Chen J, Huang S, Li H, Li Y, Zeng H, Hu J, et al. . STAT3 inhibitor BBI608 reduces patient-specific primary cell viability of cervical and endometrial cancer at a clinical-relevant concentration. Clin Trans Oncology: Off Publ Fed Spanish Oncol Societies Natl Cancer Institute Mexico. (2023) 25:662–72. doi: 10.1007/s12094-022-02970-0 PubMed DOI

Gao J, Tian J, Lv Y, Shi F, Kong F, Shi H, et al. . Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Sci. (2009) 100:389–95. doi: 10.1111/j.1349-7006.2008.01053.x PubMed DOI PMC

Liu H, Li C, Yang J, Sun Y, Zhang S, Yang J, et al. . Long noncoding RNA CASC9/miR-519d/STAT3 positive feedback loop facilitate the glioma tumourigenesis. J Cell Mol Med. (2018) 22:6338–44. doi: 10.1111/jcmm.13932 PubMed DOI PMC

Dong P, Xiong Y, Yue J, Hanley SJB, Kobayashi N, Todo Y, et al. . Exploring lncRNA-mediated regulatory networks in endometrial cancer cells and the tumor microenvironment: advances and challenges. Cancers. (2019. b) 11:234. doi: 10.3390/cancers11020234 PubMed DOI PMC

Ahn J-H, Choi YS, Choi J-H. Leptin promotes human endometriotic cell migration and invasion by up-regulating MMP-2 through the JAK2/STAT3 signaling pathway. Mol Hum Reprod. (2015) 21:792–802. doi: 10.1093/molehr/gav039 PubMed DOI

Esposito G, Bravi F, Serraino D, Parazzini F, Crispo A, Augustin LSA, et al. . “Diabetes risk reduction diet and endometrial cancer risk. Nutrients. (2021) 13:26305. doi: 10.3390/nu13082630 PubMed DOI PMC

Stenckova M, Liu Y, Nekulova M, Holcakova J, Pokorna Z, Nenutil R, et al. . ΔNp63 is regulated by insulin/IGF-1 signaling in normal basal/progenitor mammary cells and in luminal-type breast cancer cells. Neoplasma. (2023) 70:621–32. doi: 10.4149/neo_2023_230719N376 PubMed DOI

Franchi M, Asciutto R, Nicotra F, Merlino L, Vecchia CLa, Corrao G, et al. . Metformin, other antidiabetic drugs, and endometrial cancer risk: A nested case-control study within italian healthcare utilization databases. Eur J Cancer Prev. (2017) 26:225–31. doi: 10.1097/CEJ.0000000000000235 PubMed DOI

Wallbillich JJ, Josyula S, Saini U, Zingarelli RA, Dorayappan KDP, Riley MK, et al. . “High glucose-mediated STAT3 activation in endometrial cancer is inhibited by metformin: therapeutic implications for endometrial cancer. PloS One. (2017) 12:e01703185. doi: 10.1371/journal.pone.0170318 PubMed DOI PMC

Tzavlaki K, Moustakas A. TGF-β Signaling. Biomolecules. (2020) 10:487. doi: 10.3390/biom10030487 PubMed DOI PMC

Eritja N, Felip I, Dosil MA, Vigezzi L, Mirantes C, Yeramian A, et al. . A Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF-β in mouse endometrium. Cell Death Differentiation. (2017) 24:1443–58. doi: 10.1038/cdd.2017.73 PubMed DOI PMC

Pisklova M, Osmak G, Favorova O. Regulation of SMAD signaling pathway by miRNAs associated with myocardial fibrosis: in silico analysis of target gene networks. Biochem Biokhimiia. (2022) 87:832–38. doi: 10.1134/S0006297922080144 PubMed DOI

Chaudhary R, Goodman LS, Wang S, Asimakopoulos A, Weiskirchen R, Dooley S, et al. . “Cholesterol modulates type I/II TGF-β Receptor complexes and alters the balance between smad and akt signaling in hepatocytes. Commun Biol. (2024) 7:85. doi: 10.1038/s42003-023-05654-9 PubMed DOI PMC

Liu J-L, He J-P, Zhu C, Cheng H-Z. Endometrial carcinoma may favor partial, but not complete, loss of the TGF-β signaling pathway. Proc Natl Acad Sci United States America. (2019) 116:9164–65. doi: 10.1073/pnas.1903646116 PubMed DOI PMC

Fukuda T, Suzuki E, Fukuda R. Bone morphogenetic protein signaling is a possible therapeutic target in gynecologic cancer. Cancer Sci. (2022) 114:722–29. doi: 10.1111/cas.15682 PubMed DOI PMC

Safavi P, Moghadam KB, Haghighi Z, Ferns GA, Rahmani F. “Interplay between lncRNA/miRNA and TGF-β Signaling in the tumorigenesis of gynecological cancer. Curr Pharm Design luty. (2024) 30(5):352–61. doi: 10.2174/0113816128284380240123071409 PubMed DOI

Li Y, Liu Q, McGrail DJ, Dai H, Li K, Lin S-Y. CHD4 mutations promote endometrial cancer stemness by activating TGF-beta signaling. Am J Cancer Res. (2018) 8:903–14. PubMed PMC

Wang P, Zhang T, Jiang N, Wang K, Feng L, Liu T, et al. . PDIA6, which is regulated by TRPM2-AS/miR-424-5p axis, promotes endometrial cancer progression via TGF-beta pathway. Cell Death Dis. (2023) 14:1–12. doi: 10.1038/s41419-023-06297-8 PubMed DOI PMC

Konno T, Kohno T, Kikuchi S, Kura A, Saito K, Okada T, et al. . The interplay between the epithelial permeability barrier, cell migration and mitochondrial metabolism of growth factors and their inhibitors in a human endometrial carcinoma cell line. Tissue Barriers. (2024) 0:2304443. doi: 10.1080/21688370.2024.2304443 PubMed DOI PMC

Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie MW, et al. . Focal irradiation and systemic TGFβ Blockade in metastatic breast cancer. Clin Cancer Res. (2018) 24:2493–504. doi: 10.1158/1078-0432.CCR-17-3322 PubMed DOI PMC

Liu J, Tian T, Liu X, Cui Z. BCHE as a prognostic biomarker in endometrial cancer and its correlation with immunity. J Immunol Res. (2022) 2022:6051092. doi: 10.1155/2022/6051092 PubMed DOI PMC

Xu H, Yin Y, Li Y, Shi N, Xie W, Luo W, et al. . FLOT2 promotes nasopharyngeal carcinoma progression through suppression of TGF-β pathway via facilitating CD109 expression. iScience. (2023) 27:108580. doi: 10.1016/j.isci.2023.108580 PubMed DOI PMC

Jin X, Xu H, Hu Q, Yin Y, Qin M, Xia Z. Early growth response 2, a novel target of pelvic organ prolapse, is highly expressed in anterior vaginal wall tissues with pelvic organ prolapse. Histochem Cell Biol. (2024) 161:195–205. doi: 10.1007/s00418-023-02240-2 PubMed DOI

Gao Q, Huang Q, Li F, Luo F. LncRNA MCTP1-AS1 regulates EMT process in endometrial cancer by targeting the miR-650/SMAD7 axis. OncoTargets Ther. (2021) 14:751–61. doi: 10.2147/OTT.S240010 PubMed DOI PMC

Zhao T, Sun R, Ma X, Wei L, Hou Y, Song K, et al. . Overexpression of LPCAT1 enhances endometrial cancer stemness and metastasis by changing lipid components and activating TGF-β/Smad2/3 signaling pathway. Acta Biochim Biophys Sin. (2022) 54:904–16. doi: 10.3724/abbs.2022076 PubMed DOI PMC

Frank D, Moussi CJ, Ulferts S, Lorenzen L, Schwan C, Grosse R. Vesicle-associated actin assembly by formins promotes TGFβ-induced ANGPTL4 trafficking, secretion and cell invasion. Advanced Sci (Weinheim Baden-Wurttemberg Germany). (2023) 10:e2204896. doi: 10.1002/advs.202204896 PubMed DOI PMC

Li X, Kaur N, Albahrani M, Karpf AR, Black AR, Black JD. Crosstalk between protein kinase C α and transforming growth factor β Signaling mediated by runx2 in intestinal epithelial cells. J Biol Chem. (2023) 299:1030175. doi: 10.1016/j.jbc.2023.103017 PubMed DOI PMC

Driva TS, Schatz C, Sobočan M, Haybaeck J. “The Role of mTOR and eIF Signaling in Benign Endometrial Diseases. Int J Mol Sci. (2022) 23:34165. doi: 10.3390/ijms23073416 PubMed DOI PMC

Zeng H, Lu Bo, Zamponi R, Yang Z, Wetzel K, Loureiro J, et al. . mTORC1 signaling suppresses wnt/β-catenin signaling through DVL-dependent regulation of wnt receptor FZD level. Proc Natl Acad Sci United States America. (2018) 115:E10362–69. doi: 10.1073/pnas.1808575115 PubMed DOI PMC

Fatima I, Barman S, Rai R, Thiel KW, Chandra V. “Targeting wnt signaling in endometrial cancer. Cancers. (2021) 13:23515. doi: 10.3390/cancers13102351 PubMed DOI PMC

Pietrus M, Pitynski K, Waligora M, Milian-Ciesielska K, Ludwin A, Socha MW, et al. . “Association of membranous WNT-1 and nuclear mTOR with endometrial cancer grade. Int J Mol Sci. (2023) 24:83425. doi: 10.3390/ijms24098342 PubMed DOI PMC

Xu X, Kong X, Liu T, Zhou L, Wu J, Fu J, et al. . Metastasis-Associated Protein 1, Modulated by miR-30c, Promotes Endometrial Cancer Progression through AKT/mTOR/4E-BP1 Pathway. Gynecologic Oncol. (2019) 154:207–17. doi: 10.1016/j.ygyno.2019.04.005 PubMed DOI

Jin Li, Feng X, Luo D. Adiponectin regulates the Malignant biological behavior of endometrial cancer cells via AMPK/mTOR signal pathway. Trop J Pharm Res. (2021) 20:933–38. doi: 10.4314/tjpr.v20i5.7 DOI

Alizadeh A, Goldeberg D. The role of key oncogenes in reprogramming of glycolysis in cancer cells; an overview. (2022). doi: 10.13140/RG.2.2.31466.59840/1 DOI

Liao J, Chen H, Qi M, Wang J, Wang M. MLLT11-TRIL complex promotes the progression of endometrial cancer through PI3K/AKT/mTOR signaling pathway. Cancer Biol Ther. (2022) 23:211–24. doi: 10.1080/15384047.2022.2046450 PubMed DOI PMC

Deng B, Kong W, Suo H, Shen X, Newton MA, Burkett WC, et al. . Oleic acid exhibits anti-proliferative and anti-invasive activities via the PTEN/AKT/mTOR pathway in endometrial cancer. Cancers. (2023) 15:5407. doi: 10.3390/cancers15225407 PubMed DOI PMC

Yan Y, Wang S, Zhang Z, Tang M, Zhao AZ, Li Z, et al. . FKBP38 suppresses endometrial cancer cell proliferation and metastasis by inhibiting the mTOR pathway. Arch Biochem Biophysics. (2024) 752:109891. doi: 10.1016/j.abb.2024.109891 PubMed DOI

Mitamura T, Dong P, Ihira K, Kudo M, Watari H. Molecular-targeted therapies and precision medicine for endometrial cancer. Japanese J Clin Oncol. (2019) 49:108–20. doi: 10.1093/jjco/hyy159 PubMed DOI

Yang X, Liu Z, Tang W, Pratap UP, Collier AB, Altwegg KA, et al. . PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis. Mol Oncol. (2023). doi: 10.1002/1878-0261.13539 PubMed DOI PMC

McConechy MK, Ding J, Cheang MCu, Wiegand K, Senz J, Tone A, et al. . “Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. (2012) 228:20–305. doi: 10.1002/path.4056 PubMed DOI PMC

Bhatti GK, Khullar N, Sidhu IS, Navik US, Reddy AP, Reddy PH. Emerging role of non-coding RNA in health and disease. Metab Brain Dis. (2021) 36:1119–34. doi: 10.1007/s11011-021-00739-y PubMed DOI PMC

Statello L, Guo C-J, Chen L-L, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. (2021) 22:96–118. doi: 10.1038/s41580-020-00315-9 PubMed DOI PMC

Panni S, Lovering RC, Porras P, Orchard S. Non-coding RNA regulatory networks. Biochim Et Biophys Acta Gene Regul Mech. (2020) 1863 6:194417. doi: 10.1016/j.bbagrm.2019.194417 PubMed DOI

Yan H, Bu P. Non-coding RNA in cancer. Essays Biochem. (2021) 65:625–39. doi: 10.1042/EBC20200032 PubMed DOI PMC

Zhou X, Ao X, Jia Z, Li Y, Kuang S, Du C, et al. . Non-coding RNA in cancer drug resistance: underlying mechanisms and clinical applications. Front Oncol. (2022) 12:951864. doi: 10.3389/fonc.2022.951864 PubMed DOI PMC

Chen B, Dragomir MP, Yang C, Li Q, Horst D, Calin GA. Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduction Targeted Ther. (2022) 7:1–205. doi: 10.1038/s41392-022-00975-3 PubMed DOI PMC

Toden S, Zumwalt TJ, Goel A. Non-coding RNAs and potential therapeutic targeting in cancer. Biochim Biophys Acta Rev Cancer. (2021) 1875:188491. doi: 10.1016/j.bbcan.2020.188491 PubMed DOI PMC

Zhu Y, Shen Y, Chen R, Li H, Wu Y, Zhang F, et al. . KCNQ1OT1 lncRNA affects the proliferation, apoptosis, and chemoresistance of small cell lung cancer cells via the JAK2/STAT3 axis. Ann Trans Med. (2021) 9:891. doi: 10.21037/atm-21-1761 PubMed DOI PMC

Dey P, Buragohain T, Das M, Banerjee S. Exploring the role of non-coding RNA mediated regulation of signaling pathways in endometrial cancer. Adv Cancer Biol - Metastasis. (2023) 9:100111. doi: 10.1016/j.adcanc.2023.100111 DOI

Li X, Jia L, Ouyang J, An Y, Luo G, Song R, et al. . A PRISMA-compliant systematic review and meta-analysis of integrated chinese and western medicine in treating hepatitis C. Medicine. (2020) 99:e21825. doi: 10.1097/MD.0000000000021825 PubMed DOI PMC

Li S, Shan Y, Li X, Zhang C, Wei S, Dai S, et al. . lncRNA SNHG5 modulates endometrial cancer progression via the miR-25-3p/BTG2 axis. J Oncol. (2019) 2019:7024675. doi: 10.1155/2019/7024675 PubMed DOI PMC

Liu Q-W, He Y, Xu WW. Molecular functions and therapeutic applications of exosomal noncoding RNAs in cancer. Exp Mol Med. (2022) 54:216–25. doi: 10.1038/s12276-022-00744-w PubMed DOI PMC

Liu Y, Yuan H, He T. Downregulated circular RNA hsa_circ_0005797 inhibits endometrial cancer by modulating microRNA-298/catenin delta 1 signaling. Bioengineered. (2022) 13:4634–45. doi: 10.1080/21655979.2021.2013113 PubMed DOI PMC

Lai T, Qiu H, Si L, Zhen Yu, Chu D, Guo R. Long noncoding RNA BMPR1B-AS1 facilitates endometrial cancer cell proliferation and metastasis by sponging miR-7-2-3p to modulate the DCLK1/akt/NF-κB pathway. Cell Cycle (Georgetown Tex.). (2022) 21:1599–618. doi: 10.1080/15384101.2022.2060003 PubMed DOI PMC

Chen S, Liang Y, Shen Y, Wang X. lncRNA XIST/miR-129-2-3p axis targets CCP110 to regulate the proliferation, invasion and migration of endometrial cancer cells. Exp Ther Med. (2023) 25:159. doi: 10.3892/etm.2023.11858 PubMed DOI PMC

Guo J-L, Tang T, Li J-H, Yang Y-H, Zhang L, Quan Yi. LncRNA HEIH enhances paclitaxel-tolerance of endometrial cancer cells via activation of MAPK signaling pathway. Pathol Oncol Research: POR. (2020) 26:1757–66. doi: 10.1007/s12253-019-00718-w PubMed DOI

Kim LK, Park S-A, Nam EJi, Kim YT, Heo T-H, Kim HJ. LncRNA SNHG4 modulates EMT signal and antitumor effects in endometrial cancer through transcription factor SP-1. Biomedicines. (2023) 11:1018. doi: 10.3390/biomedicines11041018 PubMed DOI PMC

Kok VC, Yu C-C. Cancer-derived exosomes: their role in cancer biology and biomarker development. Int J Nanomedicine. (2020) 15:8019–36. doi: 10.2147/IJN.S272378 PubMed DOI PMC

Han Q-F, Li W-J, Hu K-S, Gao J, Zhai W-L, Yang J-H, et al. . Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer. Mol Cancer. (2022) 21:207. doi: 10.1186/s12943-022-01671-0 PubMed DOI PMC

Rajagopal C, Harikumar KB. The origin and functions of exosomes in cancer. Front Oncol. (2018) 8:66. doi: 10.3389/fonc.2018.00066 PubMed DOI PMC

Zhou L, Wang W, Wang F, Yang S, Hu J, Lu B, et al. . Plasma-derived exosomal miR-15a-5p as a promising diagnostic biomarker for early detection of endometrial carcinoma. Mol Cancer. (2021) 20:57. doi: 10.1186/s12943-021-01352-4 PubMed DOI PMC

Chen CY, Chen J, He L, Stiles BL. PTEN: tumor suppressor and metabolic regulator. Front Endocrinol (Lausanne). (2018) 9:338. doi: 10.3389/fendo.2018.00338 PubMed DOI PMC

Liu J, Ren L, Li S, Li W, Zheng X, Yang Y, et al. . The biology, function, and applications of exosomes in cancer. Acta Pharm Sinica B. (2021) 11:2783–97. doi: 10.1016/j.apsb.2021.01.001 PubMed DOI PMC

Zhang X, Sai B, Wang F, Wang L, Wang Y, Zheng L, et al. . Hypoxic BMSC-Derived Exosomal miRNAs Promote Metastasis of Lung Cancer Cells via STAT3-Induced EMT. Mol Cancer. (2019) 18:40. doi: 10.1186/s12943-019-0959-5 PubMed DOI PMC

Wu Q, Zhou L, Lv D, Zhu X, Tang H. Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression. J Hematol Oncol. (2019) 12:53. doi: 10.1186/s13045-019-0739-0 PubMed DOI PMC

Steinbichler TB, Dudás József, Riechelmann H, Skvortsova I-I. The role of exosomes in cancer metastasis. Semin Cancer Biol. (2017) 44:170–81. doi: 10.1016/j.semcancer.2017.02.006 PubMed DOI

Bryja A, Zadka Łukasz, Farzaneh M, Zehtabi M, Ghasemian M, Dyszkiewicz-Konwińska M, et al. . Small extracellular vesicles - A host for advanced bioengineering and «Trojan horse» of non-coding RNAs. Life Sci. (2023) 332:122126. doi: 10.1016/j.lfs.2023.122126 PubMed DOI

Shurtleff MJ, Temoche-Diaz MM, Karfilis KV, Ri S, Schekman R. Y-Box Protein 1 Is Required to Sort microRNAs into Exosomes in Cells and in a Cell-Free Reaction. eLife. (2016) 5:e19276. doi: 10.7554/eLife.19276 PubMed DOI PMC

Zhang Yu, Wei Y-J, Zhang Y-F, Liu H-W, Zhang Y-F. Emerging functions and clinical applications of exosomal ncRNAs in ovarian cancer. Front Oncol. (2021) 11:765458. doi: 10.3389/fonc.2021.765458 PubMed DOI PMC

Li X, Tang M. Exosomes Released from M2 Macrophages Transfer miR-221-3p Contributed to EOC Progression through Targeting CDKN1B. Cancer Med. (2020) 9:5976–88. doi: 10.1002/cam4.3252 PubMed DOI PMC

Pan X, Hong X, Lai J, Cheng Lu, Cheng Y, Yao M, et al. . Exosomal microRNA-221-3p confers adriamycin resistance in breast cancer cells by targeting PIK3R1. Front Oncol. (2020) 10:441. doi: 10.3389/fonc.2020.00441 PubMed DOI PMC

Fan J-T, Zhou Z-Y, Luo Y-L, Luo Q, Chen S-B, Zhao J-C, et al. . Exosomal lncRNA NEAT1 from Cancer-Associated Fibroblasts Facilitates Endometrial Cancer Progression via miR-26a/b-5p-Mediated STAT3/YKL-40 Signaling Pathway. Neoplasia (New York N.Y.). (2021) 23:692–703. doi: 10.1016/j.neo.2021.05.004 PubMed DOI PMC

Xie H, Yao J, Wang Y, Ni B. Exosome-Transmitted circVMP1 Facilitates the Progression and Cisplatin Resistance of Non-Small Cell Lung Cancer by Targeting miR-524-5p-METTL3/SOX2 Axis. Drug Delivery. (2022) 29:1257–71. doi: 10.1080/10717544.2022.2057617 PubMed DOI PMC

Tang X-H, Guo T, Gao X-Y, Wu X-L, Xing X-F, Ji J-F, et al. . Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications. Mol Cancer. (2021) 20:99. doi: 10.1186/s12943-021-01396-6 PubMed DOI PMC

Yang C, Wu S, Mou Z, Zhou Q, Dai X, Ou Y, et al. . Exosome-derived circTRPS1 promotes Malignant phenotype and CD8+ T cell exhaustion in bladder cancer microenvironments. Mol Therapy: J Am Soc Gene Ther. (2022) 30:1054–70. doi: 10.1016/j.ymthe.2022.01.022 PubMed DOI PMC

Lu Q, Wang X, Zhu Ji, Fei X, Chen H, Li C. Hypoxic tumor-derived exosomal circ0048117 facilitates M2 macrophage polarization acting as miR-140 sponge in esophageal squamous cell carcinoma. OncoTargets Ther. (2020) 13:1883–97. doi: 10.2147/OTT.S284192 PubMed DOI PMC

Xu Z, Chen Yi, Ma L, Chen Y, Liu J, Guo Y, et al. . Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment. Mol Therapy: J Am Soc Gene Ther. (2022) 30:3133–54. doi: 10.1016/j.ymthe.2022.01.046 PubMed DOI PMC

Yin Zi, Ma T, Huang B, Lin L, Zhou Yu, Yan J, et al. . Macrophage-Derived Exosomal microRNA-501-3p Promotes Progression of Pancreatic Ductal Adenocarcinoma through the TGFBR3-Mediated TGF-β Signaling Pathway. J Exp Clin Cancer Research: CR. (2019) 38:310. doi: 10.1186/s13046-019-1313-x PubMed DOI PMC

Fang T, Lv H, Lv G, Li T, Wang C, Han Q, et al. . Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat Commun. (2018) 9:191. doi: 10.1038/s41467-017-02583-0 PubMed DOI PMC

Hashemipour M, Boroumand H, Mollazadeh S, Tajiknia V, Nourollahzadeh Z, Borj MR, et al. . “Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers. Gynecologic Oncol. (2021) 161:314–275. doi: 10.1016/j.ygyno.2021.02.004 PubMed DOI

Sommella E, Capaci V, Aloisio M, Salviati E, Campiglia P, Molinario G, et al. . A label-free proteomic approach for the identification of biomarkers in the exosome of endometrial cancer serum. Cancers. (2022) 14:6262. doi: 10.3390/cancers14246262 PubMed DOI PMC

Maida Y, Takakura M, Nishiuchi T, Yoshimoto T, Kyo S. Exosomal transfer of functional small RNAs mediates cancer-stroma communication in human endometrium. Cancer Med. (2016) 5:304–14. doi: 10.1002/cam4.545 PubMed DOI PMC

Esfandyari S, Elkafas H, Chugh RM, Park H-S, Navarro A, Al-Hendy A. Exosomes as biomarkers for female reproductive diseases diagnosis and therapy. Int J Mol Sci. (2021) 22:2165. doi: 10.3390/ijms22042165 PubMed DOI PMC

Song Y, Wang M, Tong H, Tan Y, Hu X, Wang K, et al. . Plasma exosomes from endometrial cancer patients contain LGALS3BP to promote endometrial cancer progression. Oncogene. (2021) 40:633–46. doi: 10.1038/s41388-020-01555-x PubMed DOI

Sykaras AG, Christofidis K, Politi E, Theocharis S. Exosomes on endometrial cancer: A biomarkers treasure trove? Cancers. (2022) 14:17335. doi: 10.3390/cancers14071733 PubMed DOI PMC

Zheng W, Yang J, Wang Y, Liu X. Exosomal miRNA-93 and miRNA-205 expression in endometrial cancer. J King Saud Univ - Sci. (2020) 32:1111–15. doi: 10.1016/j.jksus.2019.10.006 DOI

Zhang K, Cai Y, Zhou Qi, Sun H, Wei J. Long non-coding RNA SNHG14 impedes viability, migration and invasion of endometrial carcinoma cells through modulating miR-93-5p/ZBTB7A axis. Cancer Manage Res. (2020) 12:9515–25. doi: 10.2147/CMAR.S257419 PubMed DOI PMC

Zhang Na, Wang Y, Liu H, Shen W. Extracellular vesicle encapsulated microRNA-320a inhibits endometrial cancer by suppression of the HIF1α/VEGFA axis. Exp Cell Res. (2020) 394:112113. doi: 10.1016/j.yexcr.2020.112113 PubMed DOI

Li B-L, Lu W, Qu J-J, Ye L, Du G-Q, Wan X-P. Loss of exosomal miR-148b from cancer-associated fibroblasts promotes endometrial cancer cell invasion and cancer metastasis. J Cell Physiol. (2019) 234:2943–53. doi: 10.1002/jcp.27111 PubMed DOI

Jing L, Hua Xu, Yuanna Du, Rukun Z, Junjun M. Exosomal miR-499a-5p Inhibits Endometrial Cancer Growth and Metastasis via Targeting VAV3. Cancer Manage Res. (2020) 12:13541–52. doi: 10.2147/CMAR.S283747 PubMed DOI PMC

Xiao Li, He Y, Peng F, Yang J, Yuan C. Endometrial Cancer Cells Promote M2-Like Macrophage Polarization by Delivering Exosomal miRNA-21 under Hypoxia Condition. J Immunol Res. (2020) 2020:9731049. doi: 10.1155/2020/9731049 PubMed DOI PMC

Wang Y, Ma H, Li Y, Su R. MiR-192-5p-modified tumor-associated macrophages-derived exosome suppressed endometrial cancer progression through targeting IRAK1/NF-κB signaling. Reprod Sci (Thousand Oaks Calif.). (2022) 29:436–47. doi: 10.1007/s43032-021-00789-8 PubMed DOI

Shi S, Tan Q, Feng F, Huang H, Liang J, Cao D, et al. . Identification of core genes in the progression of endometrial cancer and cancer cell-derived exosomes by an integrative analysis. Sci Rep. (2020) 10:9862. doi: 10.1038/s41598-020-66872-3 PubMed DOI PMC

Zhou W-J, Zhang J, Xie F, Wu J-N, Ye J-F, Wang J, et al. . CD45RO-CD8+ T cell-derived exosomes restrict estrogen-driven endometrial cancer development via the ERβ/miR-765/PLP2/notch axis. Theranostics. (2021) 11:5330–45. doi: 10.7150/thno.58337 PubMed DOI PMC

Zhou Y, Zhang Y, Gong H, Luo S, Cui Y. The role of exosomes and their applications in cancer. Int J Mol Sci. (2021) 22:12204. doi: 10.3390/ijms222212204 PubMed DOI PMC

Wang J, Gong X, Yang L, Li L, Gao X, Ni T, et al. . Loss of exosomal miR-26a-5p contributes to endometrial cancer lymphangiogenesis and lymphatic metastasis. Clin Trans Med. (2022) 12:e846. doi: 10.1002/ctm2.846 PubMed DOI PMC

Che X, Jian F, Chen C, Liu C, Liu G, Feng W. PCOS serum-derived exosomal miR-27a-5p stimulates endometrial cancer cells migration and invasion. J Mol Endocrinol. (2020) 64:1–12. doi: 10.1530/JME-19-0159 PubMed DOI

Pan Y, Wang X, Li Y, Yan P, Zhang H. Human Umbilical Cord Blood Mesenchymal Stem Cells-Derived Exosomal microRNA-503-3p Inhibits Progression of Human Endometrial Cancer Cells through Downregulating MEST. Cancer Gene Ther. (2022) 29:1130–39. doi: 10.1038/s41417-021-00416-3 PubMed DOI

Fan X, Zou X, Liu C, Cheng W, Zhang S, Geng X, et al. . MicroRNA expression profile in serum reveals novel diagnostic biomarkers for endometrial cancer. Bioscience Rep. (2021) 41:BSR20210111. doi: 10.1042/BSR20210111 PubMed DOI PMC

Jia J, Guo S, Zhang D, Tian X, Xie X. Exosomal-lncRNA DLEU1 accelerates the proliferation, migration, and invasion of endometrial carcinoma cells by regulating microRNA-E2F3. OncoTargets Ther. (2020) 13:8651–63. doi: 10.2147/OTT.S262661 PubMed DOI PMC

Qiu J, Hua K. Exosomal long noncoding RNA-NONHAT076754 faciliates endometriosis invasion and predicts endometriosis recurrence. J Minimally Invasive Gynecology. (2019) 26:S12. doi: 10.1016/j.jmig.2019.09.044 DOI

Xu H, Gong Z, Shen Y, Fang Y, Zhong S. Circular RNA expression in extracellular vesicles isolated from serum of patients with endometrial cancer. Epigenomics. (2018) 10:187–97. doi: 10.2217/epi-2017-0109 PubMed DOI

Gu X, Shi Y, Dong M, Jiang Li, Yang J, Liu Z. Exosomal transfer of tumor-associated macrophage-derived hsa_circ_0001610 reduces radiosensitivity in endometrial cancer. Cell Death Dis. (2021) 12:818. doi: 10.1038/s41419-021-04087-8 PubMed DOI PMC

Qian T, Yu X, Xu A, Li H, Chen W, Zhong S. tRF-20-S998LO9D inhibits endometrial carcinoma by upregulating SESN2. Epigenomics. (2022) 14:1563–77. doi: 10.2217/epi-2022-0349 PubMed DOI

Liu Y, Bailey JT, Abu-Laban M, Li S, Chen C, Glick AB, et al. . Photocontrolled miR-148b nanoparticles cause apoptosis, inflammation and regression of ras induced epidermal squamous cell carcinomas in mice. Biomaterials. (2020) 256:120212. doi: 10.1016/j.biomaterials.2020.120212 PubMed DOI PMC

Doyle LM, Wang MZ. “Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells. (2019) 8:7275. doi: 10.3390/cells8070727 PubMed DOI PMC

Chen S, Lu H, Jiang S, Li M, Weng H, Zhu J, et al. . An analysis of clinical characteristics and prognosis of endometrioid ovarian cancer based on the SEER database and two centers in China. BMC Cancer. (2023) 23(1):608. PubMed PMC

Das S, Saha R, Das C, Deb M, Kamilya G. Prognostic Role of Human Epididymis Protein4 (HE4) in Endometrial Lesions: Study in a Tertiary Care Centre. Indian J Surg Oncol. (2023) 14(2):428–33. PubMed PMC

Barr CE, Sergeant JC, Agnew HJ, Bolton J, McVey RJ, Crosbie EJ. Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study. BJOG. (2023) 130(8):941–8. PubMed

Yue XN, He XY, Wu JJ, Fan W, Zhang HJ, Wang CW. Endometrioid adenocarcinoma: combined multiparametric MRI and tumour marker HE4 to evaluate tumour grade and lymphovascular space invasion. Clin Radiol. (2023) 78(8):e574–81. PubMed

Zhai ZY, Li H, Li LW, Shen ZH, Zhang XB, Wang ZQ, et al. . [Prognosis analysis of radical or modified radical hysterectomy and simple hysterectomy in patients with stage II endometrial cancer]. Zhonghua Fu Chan Ke Za Zhi. (2023) 58(6):442–50. PubMed

Cheng C, Jenkins N, Aikman N, ElSahwi K. Secondary cytoreductive surgery in recurrent clear cell carcinoma of the endometrium: A case report. Int J Surg Case Rep. (2023) 108:108412. PubMed PMC

Sezgin B, Camuzcuoğlu A, Camuzcuoğlu H. Laparoscopic Resection of An Extragastrointestinal Stromal Tumor in the Presacral Area. J Minim Invasive Gynecol. (2019) 26(5):812–3. PubMed

Gök F, Ekin S, Karaman E, Erten R, Yıldız D, Bakır A. Total Sialic Acid, Antioxidant Enzyme Activities, Trace Elements, and Vitamin Status Before and After Surgery in Women with Uterine Myoma and Endometrial Cancer. Reprod Sci. (2023) 30(9):2743–57. PubMed

Thavaneswaran S, Kansara M, Lin F, Espinoza D, Grady JP, Lee CK, et al. . A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations. Br J Cancer. (2023) 129(3):475–85. PubMed PMC

Huang H, Cai X, Lin J, Wu Q, Zhang K, Lin Y, et al. . A novel five-gene metabolism-related risk signature for predicting prognosis and immune infiltration in endometrial cancer: A TCGA data mining. Comput Biol Med. (2023) 155:106632. PubMed

Zhao J, Jiao W, Sui X, Zou J, Wang J, Lin Z. Construction of a prognostic model of luteolin for endometrial carcinoma. Am J Transl Res. (2023) 15(3):2122–39. PubMed PMC

Moroney MR, Davies KD, Wilberger AC, Sheeder J, Post MD, Berning AA, et al. . Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers. Gynecol Oncol. (2019) 153(3):517–20. PubMed PMC

Raffone A, Travaglino A, Saccone G, Viggiani M, Giampaolino P, Insabato L, et al. . PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis. Arch Gynecol Obstet. (2019) 299(6):1511–24. PubMed

Hu TWY, Li L, Yang E, Nie D, Li ZY. Molecular expression characteristics confirm the malignancy concealed by morphological alterations in endometrial cancer after fertility-preserving treatment. Arch Gynecol Obstet. (2019) 299(6):1673–82. PubMed

Bamberger AM, Briese J, Götze J, Erdmann I, Schulte HM, Wagener C, et al. . Stimulation of CEACAM1 expression by 12-O-tetradecanoylphorbol-13-acetate (TPA) and calcium ionophore A23187 in endometrial carcinoma cells. Carcinogenesis. (2006) 27(3):483–90. PubMed

Li X, Cheng Y, Dong Y, Shen B, Yang X, Wang J, et al. . An elevated preoperative serum calcium level is a significant predictor for positive peritoneal cytology in endometrial carcinoma. Chin J Cancer Res. (2019) 31(6):965–73. PubMed PMC

Ge L, Liu G, Hu K, Huang K, Zhang M, Zhou J, et al. . A New Risk Index Combining d-Dimer, Fibrinogen, HE4, and CA199 Differentiates Suspecting Endometrial Cancer From Patients With Abnormal Vaginal Bleeding or Discharge. Technol Cancer Res Treat. (2020) 19:1533033819901117. PubMed PMC

Song N, Zhang Y, Kong F, Yang H, Ma X. HOXA-AS2 promotes type I endometrial carcinoma via miRNA-302c-3p-mediated regulation of ZFX. Cancer Cell Int. (2020) 20:359. PubMed PMC

Fan JT, Zhou ZY, Luo YL, Luo Q, Chen SB, Zhao JC, et al. . Exosomal lncRNA NEAT1 from cancer-associated fibroblasts facilitates endometrial cancer progression via miR-26a/b-5p-mediated STAT3/YKL-40 signaling pathway. Neoplasia. (2021) 23(7):692–703. PubMed PMC

Unuvar S, Melekoglu R, Turkmen NB, Yilmaz E, Yasar S, Yuce H. Comparison of preoperative serum neopterin, periostin, indoleamine 2,3-dioxygenase, YKL-40, and tenascin-c levels with current tumor markers for early-stage endometrial cancer. Int J Gynaecol Obstet. (2021) 155(3):417–24. PubMed

Omer B, Genc S, Takmaz O, Dirican A, Kusku-Kiraz Z, Berkman S, et al. . The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients. Tumour Biol. (2013) 34(5):2645–50. PubMed

Ren X, Liang J, Zhang Y, Jiang N, Xu Y, Qiu M, et al. . Single-cell transcriptomic analysis highlights origin and pathological process of human endometrioid endometrial carcinoma. Nat Commun. (2022) 13(1):6300. PubMed PMC

Jiang J, Zhu J, Qiu P, Ni J, Zhu W, Wang X. HNRNPA2B1-mediated m6A modification of FOXM1 promotes drug resistance and inhibits ferroptosis in endometrial cancer via regulation of LCN2. Funct Integr Genomics. (2023) 24(1):3. PubMed

Su S, Yin L. Application of Pelvic Magnetic Resonance Imaging Scan Combined with Serum Pyruvate Kinase Isozyme M2, Neutrophil Gelatinase-Associated Lipocalin, and Soluble Leptin Receptor Detection in Diagnosing Endometrial Carcinoma. Contrast Media Mol Imaging. (2022) 2022:7197505. PubMed PMC

Dong P, Xiong Y, Yue J, Xu D, Ihira K, Konno Y, et al. . Long noncoding RNA NEAT1 drives aggressive endometrial cancer progression via miR-361-regulated networks involving STAT3 and tumor microenvironment-related genes. J Exp Clin Cancer Research : CR. (2019. a) 38:295. doi: 10.1186/s13046-019-1306-9 PubMed DOI PMC

Jimeno A, Moore KN, Gordon M, Chugh R, Diamond JR, Aljumaily R, et al. . A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Invest New Drugs. (2019) 37(3):461–72. PubMed

Guan L, Zhang A. Amniotic epithelial cells reverse abnormal vascular structure and function in endometrial carcinoma. Int J Clin Exp Pathol. (2019) 12(7):2405–24. PubMed PMC

Hassani M, Mahdevar M, Peymani M. Exploring the role of interleukin 11 in cancer progression, patient survival, and therapeutic insights. Mol Biol Rep. (2024) 51(1):461. PubMed

Lam C, Sarasohn D, Weigelt B, Zamarin D. Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer. Gynecol Oncol Rep. (2023) 49:101258. PubMed PMC

Ducceschi M, Polignano M, Bini M, Lopez S, Conca E, Tamborini E, et al. . The Revolution of Immunotherapy in Gynecological Cancers: The Lazarus Effect in Endometrial Cancer. J Clin Med. (2023) 12(17):5540. PubMed PMC

Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer Immunol Res. (2019) 7(10):1570–3. PubMed PMC

Wang K-H, Ding D-C. The role and applications of exosomes in gynecological cancer: A review. Cell Transplant. (2023) 32:9636897231195240. doi: 10.1177/09636897231195240 PubMed DOI PMC

Chang L, Zhang D, Shi H, Bian Y, Guo R. MiR-143 inhibits endometrial cancer cell proliferation and metastasis by targeting MAPK1. Oncotarget. (2017) 8:84384–95. doi: 10.18632/oncotarget.v8i48 PubMed DOI PMC

Bogaczyk A, Zawlik I, Zuzak T, Kluz M, Potocka N, Kluz T. The role of miRNAs in the development, proliferation, and progression of endometrial cancer. Int J Mol Sci. (2023) 24:114895. doi: 10.3390/ijms241411489 PubMed DOI PMC

Li X, Zha Li, Li Bo, Sun R, Liu J, Zeng iH. Clinical significance of MMP-9 overexpression in endometrial cancer: A PRISMA-compliant meta-analysis. Front Oncol. (2022) 12:925424. doi: 10.3389/fonc.2022.925424 PubMed DOI PMC

Maqsood Q, Sumrin A, Saleem Y, Wajid A, Mahnoor M. Exosomes in cancer: diagnostic and therapeutic applications. Clin Med Insights: Oncol. (2024) 18. doi: 10.1177/11795549231215966 PubMed DOI PMC

Li S, Shan Y, Li X, Zhang C, Wei S, Dai S, et al. . lncRNA SNHG5 Modulates Endometrial Cancer Progression via the miR-25-3p/BTG2 Axis. J Oncol. (2019) 2019:7024675. doi: 10.1155/2019/7024675 PubMed DOI PMC

Li X, Liu LiLi, Yao JuL, Wang K, Ai H. Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles Inhibit Endometrial Cancer Cell Proliferation and Migration through Delivery of Exogenous miR-302a. Stem Cells Int. (2019) 2019:8108576. doi: 10.1155/2019/8108576 PubMed DOI PMC